Abstract The past decade has seen a huge increase in clinical research with psychedelic drugs and 3,4‐methylenedioxymethamphetamine (MDMA), which have revealed great potential for treating mental health conditions. Given this progress in research, as well as the current unmet clinical need of millions of patients, in 2023, the Australian Therapeutic Goods Administration (TGA) approved the use...
Ketamine has rapid-onset antidepressant activity in patients with treatment-resistant major depression (TRD). The safety and tolerability of racemic ketamine may be improved if given orally, as an extended-release tablet (R-107), compared with other routes of administration. In this phase 2 multicenter clinical trial, male and female adult patients with TRD and Montgomery-Asberg Depression...
Mindfulness meditation may improve attention and self-regulation. One component of attention and self-regulation that may allow these improvements is performance monitoring. Neural correlates of performance monitoring can be objectively measured with electroencephalogram (EEG) via the error related negativity (ERN) and error positivity (Pe). Previous research assessing the ERN and Pe in...